What does Medibio Ltd do?
Medibio Ltd [ASX:MEB] is a company which has developed an evidence based testing procedure for the diagnosis of depression and stress disorders.
It is focusing on commercialising its 15 years of research into circadian heart rate technology. It is based on the discovery that variations in circadian heart rates are sensitive measures for depression and other mental health disorders.
The technology consists of a wearable heart monitor that sends recordings wirelessly to the internet, where a proprietary algorithm analyses and delivers a diagnosis.
Their technology also provides a tool for determining the effectiveness of treatment, because effective treatment will normalise circadian heart rates.
The company has also developed a test to measure stress levels in the workplace and its impact on health and well-being. Its wearable app technology is easily translated to the workplace, and the company is optimistic there are big revenues to come from the workplace stress and depression diagnostic market.
That’s interesting, but what is the chart telling us?
What does the chart look like?
I find it helpful to bring up a chart. The daily chart of MEB.
Despite having no customer receipts and generating negative cash flows, the company is starting to break over tops.
What now for MEB shares?
Its early days for this company, which is securing patents and conducting trials to validate their technology.
But we can watch the chart now because it will tell us in advance how the trials are progressing and whether they can commercialise their technology and start to generate some client revenues.
Use the charts to tell you what is really happening within a company, before you read about it in the announcements. You can get started on that here.
Research Analyst, Cycles, Trends and Forecasts